stockrow
Sunday 8 November 2026
Export GRFS’s income statement to Excel — free account
Grifols, S.A.
GRFSHealthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.
- Revenue
- +9.37%
- EPS
- +59.8%
- Free cash flow
- +4.11%
- Total debt
- −6.08%
Quarter to September 2026, against a year earlier
8.43
0.03
−0.35%
Follow GRFS
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
15.81 | — | 17.34 | 20.22 |
+8 more quarters Free account |
P/S ratio |
0.56 | — | 0.63 | 0.75 | |
P/FCF ratio |
6.63 | — | 9.06 | 9.85 | |
P/Operating CF |
12.51 | — | 42.39 | 13.70 | |
P/B ratio |
0.52 | — | 0.59 | 0.74 | |
Price to Tangible BV |
0.00 | — | 0.00 | 0.00 | |
EV/Sales |
1.68 | — | 1.84 | 1.91 | |
EV/EBITDA |
7.99 | — | 8.23 | 8.51 | |
EV/Operating CF |
11.81 | — | 13.57 | 13.76 | |
EV/FCF |
19.74 | — | 26.37 | 25.24 | |
Quick Ratio |
0.74 | 0.70 | 0.76 | 0.80 | |
Current Ratio |
2.33 | 2.37 | 2.47 | 2.51 | |
Net Debt/EBITDA |
21.80 | 0.00 | 25.10 | 22.27 | |
Debt/Assets |
45.56% | 46.57% | 48.16% | 48.92% | |
Debt/Equity |
1.12 | 1.17 | 1.23 | 1.27 | |
Asset Turnover |
0.38 | 0.00 | 0.38 | 0.38 | |
Operating CF/Net income |
2.13 | 0.00 | 1.51 | 4.20 | |
Capex/Depreciation |
(1.00) | (1.09) | (0.87) | (1.02) | |
Interest Coverage |
2.56 | — | 1.81 | 1.68 | |
Research and Development Expense of Revenue |
4.26% | — | 5.29% | 6.87% | |
Selling, General and Administrative Expense of Revenue |
15.98% | — | 16.53% | 14.10% | |
Intangible Assets out of Total Assets |
0.53 | 0.49 | 0.53 | 0.49 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | 0.00% | |
Graham Net Nets |
(1.55) | — | (1.50) | (1.25) | |
Graham Number |
0.00 | — | 0.00 | 11.47 | |
Earnings Yield |
6.33% | — | 5.77% | 4.95% | |
Free Cash Flow Yield |
15.08% | — | 11.04% | 10.15% | |
Revenue per Share |
0.00 | — | 0.00 | 3.39 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.68 | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.20) | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.48 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 1.43 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 12.64 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 12.64 | |
Free Cash Flow |
270.10 | 128.91 | 23.41 | 327.96 | |
Working Capital |
3,510.55 | 3,568.33 | 3,663.35 | 3,456.43 | |
Capital Expenditures |
(127.65) | (134.18) | (105.34) | (136.42) | |
Net Current Asset Value |
(7,703.64) | (7,912.18) | (8,165.88) | (7,959.40) | |
EV/EBIT |
10.06 | — | 11.21 | 11.59 | |
Capex to Sales |
0.05 | 0.00 | 0.05 | 0.06 | |
Price to Operating Income |
3.38 | — | 3.85 | 4.52 | |
| Other line items | |||||
Average Receivables |
1,160.98 | 997.85 | 1,031.48 | 960.73 | |
Average Payables |
— | 968.46 | — | 865.12 | |
Average Inventory |
3,953.37 | 3,929.75 | 3,880.29 | 3,764.44 | |
Average Assets |
23,275.25 | 22,899.16 | 22,800.10 | 22,303.03 | |
Average Common Equity |
9,155.25 | 8,951.89 | 8,960.87 | 7,242.39 |
Columns are period end dates · fundamentals updated 5 Nov 2026